prikaz prve stranice dokumenta Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia
  Preuzmi
PDF 5.09 MB
Znanstveni rad - Izvorni znanstveni rad
Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia
Frontiers in Pharmacology, 14 (2023); 1258151. https://doi.org/10.3389/fphar.2023.1258151
Smoljo, Tomislav; Tomic, Barbara; Lalić, Hrvoje; Dembitz, Vilma; Batinić, Josip; Bedalov, Antonio; Višnjić, Dora

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Smoljo, T., Tomic, B., Lalić, H., Dembitz, V., Batinić, J., Bedalov, A. i Višnjić, D. (2023). Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia. Frontiers in Pharmacology, 14.. doi: 10.3389/fphar.2023.1258151

Smoljo, Tomislav, et al. "Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia." Frontiers in Pharmacology, vol. 14, 2023. https://doi.org/10.3389/fphar.2023.1258151

Smoljo, Tomislav, Barbara Tomic, Hrvoje Lalić, Vilma Dembitz, Josip Batinić, Antonio Bedalov i Dora Višnjić. "Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia." Frontiers in Pharmacology 14 (2023). https://doi.org/10.3389/fphar.2023.1258151

Smoljo, T., et al. (2023) 'Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia', Frontiers in Pharmacology, 14. doi: 10.3389/fphar.2023.1258151

Smoljo T, Tomic B, Lalić H, Dembitz V, Batinić J, Bedalov A, i sur.. Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia. Frontiers in Pharmacology [Internet]. 26.10.2023. [pristupljeno 25.11.2024.];14. doi: 10.3389/fphar.2023.1258151

T. Smoljo, et al., "Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia", Frontiers in Pharmacology, vol. 14, Listopad 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:853860. [Citirano: 25.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:853860
Podaci o radu
Naslov (engleski)Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia
AutorTomislav Smoljo
AutorBarbara Tomic
AutorHrvoje Lalić
AutorVilma Dembitz
AutorJosip Batinić
AutorAntonio Bedalov
AutorDora Višnjić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(HRVATSKI INSTITUT ZA ISTRAŽIVANJE MOZGA)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA FIZIOLOGIJU I IMUNOLOGIJU)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Fiziologija čovjeka
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Low-dose cytarabine (LDAC) is a standard therapy for elderly acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. While high doses of cytarabine induce cytotoxicity, the precise mechanism of action of LDAC in AML remains elusive. In vitro studies have demonstrated LDAC-induced differentiation; however, such differentiation is seldom observed in vivo. We hypothesize that this discrepancy may be attributed to the influence of bone marrow (BM) stromal cells on AML cells. Thus, this study aimed to investigate the impact of BM stromal cells on LDAC-induced differentiation of AML cell lines and primary samples. Our results demonstrate that the presence of MS-5 stromal cells prevented LDAC-induced cell cycle arrest, DNA damage signaling and differentiation of U937 and MOLM-13 cell lines. Although transcriptomic analysis revealed that the stroma reduces the expression of genes involved in cytokine signaling and oxidative stress, data obtained with pharmacological inhibitors and neutralizing antibodies did not support the role for CXCL12, TGF-β1 or reactive oxygen species. The presence of stromal cells reduces LDAC-induced differentiation in primary samples from AML-M4 and myelodysplastic syndrome/AML patients. In conclusion, our study demonstrates that BM stroma reduces differentiation of AML induced by LDAC. These findings provide insights into the limited occurrence of terminal differentiation observed in AML patients, and suggest a potential explanation for this observation.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaFrontiers in Pharmacology
Brojčani podacivol. 14, 1258151
e-ISSN1663-9812
DOIhttps://doi.org/10.3389/fphar.2023.1258151
URN:NBNurn:nbn:hr:105:853860
Datum objave publikacije2023-10-26
URL dokumentahttps://www.frontiersin.org/articles/10.3389/fphar.2023.1258151/full
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-04-12 11:07:27